An interventional study of Optical correction values obtained with investigational device and visual acuity and Optical correction values obtained with an autorefractometer and visual acuity in Myopia, sponsored by Essilor International. Not yet recruiting at 1 site in France. Open to participants aged 18 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-22.
Sponsored by Essilor International · Not applicable, Interventional, and Screening
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies in Myopia by EssilorLuxottica — 14 open to participants now, 19 under way, none of them phase 3. Myopia · EssilorLuxottica.
Among the 28 studies in Myopia by EssilorLuxottica, this one is the 21st largest by planned enrollment, is one of 9 that started in 2025, is one of 28 with no phase, reaches primary completion later than 11 of the 18 other live ones, and was the 17th registered.
1,160 studies on the registry are indexed under Myopia; 226 are open to participants now.
Browse Myopia studies →14 of the 28 studies in Myopia by EssilorLuxottica are open now, in 5 countries. Recruiting first, the newest first:
Essilor International · Sites in Singapore
Ages 6–13
Essilor International · Sites in France
Ages 12–17 · Healthy volunteers
Essilor International · Sites in France
Ages 6–14
Essilor International · Sites in France
Ages 6–12 · Healthy volunteers
Essilor International · Sites in China
Ages 6–12
By country, each count listing its studies:
Of the 122 Myopia studies recruiting now, 19 (16%) set no upper age limit and 102 (84%) stop at 75 or younger; 86 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 39 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 9 started in 2025.
This study's planned enrollment of 30 is below the median of 79 across 924 interventional studies indexed under Myopia.
Median enrollment 52 across the 28 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Essilor International, one of the names counted as EssilorLuxottica. Under that name alone:
Essilor International is the lead sponsor of 38 studies on the registry; 20 are open to participants now.
6 of the studies in Myopia by EssilorLuxottica that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07440134Essilor InternationalVisual and Postural Behavior in Myopic and Non-Myopic Teenagers | 2027-05 |
| NCT06263946Essilor InternationalEssilor® Stellest® Lenses Multicentre European Study (SLOMES) | 2027-05-04 |
| NCT07297810Essilor InternationalDevelopment of a New Device and Method to Assess the Degree of Myopia and/or Astigmatism in Myopic People | 2027-06 |
| NCT06850168Essilor InternationalClinical Investigation of a Novel Spectacle Lens on Slowing Down Juvenile Myopia Progression | 2027-10 |
| NCT07844408Essilor InternationalStudy of Eye Fatigue From Digital Screens and Its Impact on Visual Performance in People With Normal Vision and Myopia, With and Without Dry Eye Symptoms and Signs | 2027-11 |
Add all 6 to your calendar (.ics) → With an account.
Among the 28 studies in Myopia by EssilorLuxottica, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical investigation is to check whether the new device can correctly measure a person's degree of myopia and astigmatism.
To evaluate and improve the device's performance, the results (optical correction values and the associated visual acuity) obtained with the investigational device will be compared with the results obtained using standard instruments commonly used by eye care professionals.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
General criteria for non-inclusion:
The following elements are considered based on the participant's declaration :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Optical correction values obtained with investigational device and visual acuity · Device: Optical correction values obtained with an autorefractometer and visual acuity · Device: Optical correction values obtained with a phoropter and visual acuity
Participants optical correction values are determined using the investigational device and their visual acuity is measured with this optical correction
Participants optical correction values are determined using an autorefractometer (objective refraction) and their visual acuity is measured with this optical correction
Participants optical correction values are determined using a phoropter (subjective refraction) and their visual acuity is measured with this optical correction
Difference of Optical Values
Optical correction values obtained with the investigational device are compared with the values obtained using a phoropter (gold standard method - subjective refraction)
Time frame: Day One
Difference in the proportion of visual acuity levels
Comparison of the proportion of participants reaching specific monocular visual acuity levels (≥10/10 and ≥12/10) when wearing the refraction obtained from the investigational device versus the subjective refraction obtained from a phoropter (gold standard method)
Time frame: Day One
Comparison of Monocular Visual Acuity Distribution
Comparison of the distribution of monocular visual acuity obtained using the refraction from the investigational device versus the objective refraction from an autorefractometer.
Time frame: Day One
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2025; primary completion for Jun 2027, 18 months later.
Of 234 industry-sponsored interventional studies with no phase under Myopia, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 24. This study's planned 18 months is above that.
Counting every sponsor, half of 434 studies reached it within 14 months; a quarter within 3 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.